.png){kind=icon}
.png){kind=icon}
Return
Toward a More accurate, Evidence-Based Classification of CYP Inhibitors: A Critical Appraisal of Current Systems
.png){kind=icon}
OA
AI
J
DOI：10.1002/cpt.70122.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
In this issue of CPT, Malavé et al. deliver a comprehensive reassessment of CYP2C19 inhibitor classifications through a systematic review of clinical drug–drug interaction (DDI) studies. While their findings bring clarity to specific discrepancies, this commentary explores the origins of such inconsistencies, particularly focusing on methodological, pharmacogenetic, and substrate-specific complexities. These issues prompt renewed consideration of how CYP inhibitor categories are defined, communicated, and used in clinical and regulatory settings.
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
C
IF:
5.5
Papers:
8.6K
Citations:
1.9W
Organization
Cited Papers